editorial team – Metro Research

MEI Pharma (NASDAQ:MEIP) Updated by StockNews.com to “Buy”

Roland Moore — Sat, 19 Mar 2022 05:14:13 +0000

MEI Pharma (NASDAQ: MEIP – Get a rating) has been updated by StockNews.com from a “hold” rating to a “buy” rating in a research note released Saturday.

A number of other research analysts also commented on the company. Jefferies Financial Group assumed coverage for MEI Pharma in a Thursday, Feb. 3 report. They set a “buy” rating and a price target of $4.00 for the company. HC Wainwright restated a “buy” rating and issued a target price of $10.00 on MEI Pharma shares in a research note on Tuesday, February 15. Ultimately, Zacks Investment Research downgraded MEI Pharma from a “buy” rating to a “hold” rating in a Friday, February 4 research note. One equity research analyst gave the stock a hold rating and six gave the company’s stock a buy rating. According to data from MarketBeat, MEI Pharma currently has an average rating of “Buy” and an average target price of $8.96.

MEIP shares opened at $1.78 on Friday. MEI Pharma has a 12 month minimum of $1.68 and a 12 month maximum of $3.91. The company has a market capitalization of $236.72 million, a PE ratio of -3.02 and a beta of 1.38. The stock has a 50-day moving average of $2.07 and a 200-day moving average of $2.54.

(A d)

Fungi: Oregon voted in 2020 to adopt the Psilocybin Program initiative, allowing psilocybin (the active compound in “magic mushrooms”) for therapeutic use. Today, companies like Ei. Ventures is testing psilocybin therapies in preclinical trials. Pretty cool !

MEI Pharma (NASDAQ: MEIP – Get a rating) last released its quarterly results on Thursday, February 10. The company reported EPS of $0.05 for the quarter, beating analyst consensus estimates of $0.19 ($0.14). MEI Pharma had a negative return on equity of 83.20% and a negative net margin of 123.86%. On average, stock analysts expect MEI Pharma to post EPS of -0.64 for the current fiscal year.

Several hedge funds and other institutional investors have recently changed their stock holdings. Amalgamated Bank increased its stake in MEI Pharma shares by 29.9% in the second quarter. Amalgamated Bank now owns 20,472 shares of the company valued at $58,000 after buying an additional 4,709 shares in the last quarter. Principal Financial Group Inc. increased its stake in MEI Pharma by 36.4% during the third quarter. Principal Financial Group Inc. now owns 22,945 shares of the company worth $63,000 after acquiring 6,117 additional shares in the last quarter. Citigroup Inc. increased its stake in MEI Pharma by 151.5% during the third quarter. Citigroup Inc. now owns 12,979 shares of the company worth $36,000 after acquiring 7,818 additional shares in the last quarter. Strategic Wealth Advisors Group LLC increased its stake in MEI Pharma by 5.4% during the third quarter. Strategic Wealth Advisors Group LLC now owns 165,500 shares of the company worth $457,000 after acquiring 8,500 additional shares in the last quarter. Finally, Invesco Ltd. increased its stake in MEI Pharma by 32.6% during the third quarter. Invesco Ltd. now owns 38,504 shares of the company worth $106,000 after acquiring 9,468 additional shares last quarter. Institutional investors and hedge funds hold 68.89% of the company’s shares.

About MEI Pharma (Get a rating)

MEI Pharma, Inc is a pharmaceutical company dedicated to the clinical development of cancer therapies. Its drug candidates include Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome.

Further reading

This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in MEI Pharma right now?

Before you consider MEI Pharma, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and MEI Pharma was not on the list.

Although MEI Pharma currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

NCC Group (LON:NCC) rating reiterated by Berenberg Bank

Roland Moore — Wed, 16 Mar 2022 09:15:22 +0000

NCC Group (LON:NCC – Get a rating)‘s stock had its “buy” rating reaffirmed by investment analysts at Berenberg Bank in a report on Tuesday, MarketBeat.com reports.

A number of other equity research analysts have also recently published reports on NCC. Canaccord Genuity Group reiterated a “buy” rating and set a price target of GBX 310 ($4.03) on NCC Group shares in a Monday, March 7 research report. Shore Capital reiterated a “buy” rating on NCC Group shares in a Monday, February 14, research report. One equity research analyst gave the stock a hold rating and six gave the stock a buy rating. According to MarketBeat.com, NCC Group currently has an average rating of “Buy” and a consensus price target of 327.67 GBX ($4.26).

Shares of LON:NCC opened at 188.40 GBX ($2.45) on Tuesday. The company has a quick ratio of 1.02, a current ratio of 1.03 and a debt ratio of 57.47. The company has a market capitalization of £583.69 million and a P/E ratio of 62.60. The NCC group has a 52-week minimum of 162.80 GBX ($2.12) and a 52-week maximum of 348 GBX ($4.53). The company has a 50-day moving average price of 197.51 GBX and a 200-day moving average price of 240.53 GBX.

In other news, insider Julie Chakraverty bought 9,880 shares in a trade on Thursday, February 3. The share was bought at an average cost of 187 GBX ($2.43) per share, for a total value of £18,475.60 ($24,025.49). Additionally, insider Adam Palser bought 25,000 shares in a trade on Thursday, January 27. The share was bought at an average cost of 216 GBX ($2.81) per share, for a total value of £54,000 ($70,221.07).

(A d)

This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.

About NCC Group (Get a rating)

NCC Group plc provides cybersecurity and risk mitigation services in the UK, North America, the rest of Europe and internationally. It operates through two segments, Assurance and Software Resilience. The Company provides cybersecurity services, such as penetration testing and security assessments, managed detection and response, vulnerability scanning, compliance and accreditations, risk management, products and services cloud, technology solutions, threat intelligence, specialized practices and training.

See also

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in NCC Group right now?

Before you consider NCC Group, you’ll want to hear this.

Although NCC Group currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Traders Buy Large Volume of Lilium Put Options (NASDAQ:LILM)

Roland Moore — Sun, 13 Mar 2022 01:22:23 +0000

Lilium GmbH (NASDAQ: LILM – Get a rating) saw unusually heavy options trading activity on Friday. Equity investors bought 7,069 put options on the stock. This is an increase of approximately 841% over the average volume of 751 puts.

Shares of NASDAQ LILM traded down $0.27 during Friday’s trading, hitting $3.69. 947,594 shares of the company were traded, against an average volume of 977,411. The company has a fifty-day moving average of $4.97. Lilium has a fifty-two week low of $2.96 and a fifty-two week high of $11.66.

LILM has been the subject of a number of research analyst reports. BNP Paribas launched a hedge on Lilium shares in a research report on Wednesday, November 17. They set a “neutral” rating and a price target of $10.30 on the stock. Zacks Investment Research upgraded Lilium’s shares from a “buy” rating to a “hold” rating in a Thursday, Jan. 20, research report. Barclays cut its price target on Lilium shares from $11.00 to $7.00 in a research report on Tuesday, January 18. Finally, Exane BNP Paribas launched a hedge on Lilium shares in a research report on Wednesday 17 November. They set a “neutral” rating and a price target of $10.30 on the stock. Three investment analysts gave the stock a hold rating and two gave the company a buy rating. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $12.89.

(A d)

Fortune 500 companies, semiconductor producers and even some of the biggest sportswear manufacturers are all betting big investing in a market that Bloomberg Intelligence predicts could be worth $800 billion by 2024.

Get the free report with the 4 most promising stocks to capitalize on the revolutionary Metaverse.

Several hedge funds and other institutional investors have recently changed their positions in LILM. Gibson Capital LLC acquired a new position in shares of Lilium during the third quarter valued at approximately $416,000. NewGen Asset Management Ltd acquired a new equity stake in Lilium in Q3 worth approximately $10,510,000. Advisor Group Holdings Inc. acquired a new stake in shares of Lilium in Q3 worth approximately $106,000. Allianz Asset Management GmbH acquired a new equity stake in Lilium in Q3 worth approximately $15,799,000. Finally, Geode Capital Management LLC acquired a new equity stake in Lilium in Q3 worth approximately $2,111,000. Hedge funds and other institutional investors hold 42.24% of the company’s shares.

About Lilium (Get a rating)

Qell Acquisition Corp. is a blank check company. It was formed for the purpose of a merger, stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with a or more companies. Qell Acquisition Corp. is based in San Francisco, California.

See also

Should you invest $1,000 in Lilium right now?

Before you consider Lilium, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Lilium wasn’t on the list.

Although Lilium currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Vivid Seats (NASDAQ:SEAT) rating downgraded to sell at Zacks Investment Research

Roland Moore — Fri, 11 Mar 2022 08:55:50 +0000

Live Seats (NASDAQ:SEAT – Get a rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Friday, Zacks.com reports.

According to Zacks, “Vivid Seats Inc. provides a marketplace that uses its technology platform to connect buyers with ticket sellers. Vivid Seats Inc., formerly known as Horizon Acquisition Corporation, is based in CHICAGO.”

SEAT has been the subject of several other research reports. William Blair began coverage of Vivid Seats in a research note on Tuesday, November 16. They issued an “outperformance” rating on the stock. Evercore ISI began covering Vivid Seats in a report on Tuesday, January 18. They issued a “hold” rating and a price target of $14.00 for the company. Citigroup downgraded Vivid Seats from a “neutral” rating to a “buy” rating and set a price target of $14.00 for the company in a Monday, January 3, report. Raymond James began covering Vivid Seats in a report on Thursday, November 18. They issued an “outperform” rating and a price target of $17.00 for the company. Finally, Credit Suisse Group began covering Vivid Seats in a Monday, January 31 report. They issued an “outperform” rating and a price target of $16.00 for the company. One research analyst rated the stock with a sell rating, one gave the company a hold rating and six gave the company a buy rating. According to MarketBeat, the stock has a consensus buy rating and an average target price of $15.50.

(A d)

This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.

SEAT shares opened at $10.52 on Friday. Vivid Seats has a 12 month minimum of $7.84 and a 12 month maximum of $14.35. The company’s fifty-day moving average price is $10.54.

In other news, major shareholder Benefit Life Insuranc Security sold 36,507,173 Vivid Seats shares in a trade on Tuesday, December 14. The stock was sold at an average price of $10.00, for a total value of $365,071,730.00. The sale was disclosed in an SEC filing, available at this hyperlink. In the past three months, insiders have sold 36,511,835 shares of the company valued at $365,120,681.

Major investors have recently changed their positions in the company. Wolverine Asset Management LLC acquired a new position in Vivid Seats during Q4 worth approximately $52,000. State Street Corp bought a new stock position in Vivid Seats in the fourth quarter worth about $119,000. Victory Capital Management Inc. bought a new stock position in Vivid Seats in the fourth quarter worth about $120,000. Mirabella Financial Services LLP bought a new stock position in Vivid Seats in the fourth quarter worth approximately $190,000. Finally, Cornerstone Investment Partners LLC bought a new stock position in Vivid Seats in the fourth quarter worth approximately $205,000. 55.24% of the shares are currently held by institutional investors.

About Vivid Seating (Get a rating)

Horizon Acquisition Corporation is a blank check corporation formed for the purpose of effecting a merger, stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or several companies. Although the company may pursue an initial business combination objective in any industry, it currently intends to focus its efforts on identifying companies in the financial services industry, with an emphasis on differentiated financial services and platforms adjacent to financial services.

Featured articles

Get a Free Copy of Zacks’ Research Report on Vivid Seats (SEAT)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Should you invest $1,000 in Vivid Seats right now?

Before you consider Vivid Seats, you’ll want to hear this.

Although Vivid Seats currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Research Analysts Set Petco Health and Wellness Company, Inc. Earnings Expectations for Fiscal 2022 (NASDAQ:WOOF)

Roland Moore — Wed, 09 Mar 2022 17:40:26 +0000

Petco Health and Wellness Company, Inc. (NASDAQ: WOOF – Get a rating) – Equity research analysts at Jefferies Financial Group raised their fiscal 2022 earnings per share estimates for Petco Health and Wellness in a report released Sunday, March 6. Jefferies Financial Group analyst S. Wissink now expects the company to earn $0.74 per share for the year, up from his previous estimate of $0.73. Jefferies Financial Group has a “Hold” rating and a price target of $26.00 on the stock. Petco Health and Wellness (NASDAQ: WOOF – Get a rating) last released its results on Tuesday, March 8. The company reported earnings per share of $0.28 for the quarter, beating consensus analyst estimates of $0.25 by $0.03. The company posted revenue of $1.51 billion for the quarter, versus a consensus estimate of $1.48 billion. Petco Health and Wellness recorded a return on equity of 8.27% and a net margin of 2.30%. The company’s quarterly revenue increased 13.2% year over year. In the same quarter of the previous year, the company achieved EPS of $0.17.

Other stock analysts have also recently published research reports on the company. Citigroup lowered its price target on Petco Health and Wellness from $29.00 to $25.00 in a Tuesday, January 18 report. Zacks Investment Research downgraded Petco Health and Wellness from a “buy” rating to a “hold” rating in a report on Tuesday, February 8. Wedbush upgraded Petco Health and Wellness from a “neutral” rating to an “outperforming” rating and set a price target of $23.00 on the stock in a Monday, Dec. 6 report. Needham & Company LLC launched coverage on Petco Health and Wellness in a Thursday, Dec. 16, report. They issued a “buy” rating and a price target of $30.00 on the stock. Ultimately, StockNews.com upgraded Petco Health and Wellness from a “hold” rating to a “buy” rating in a Friday, March 4, report. Two analysts rated the stock with a sell rating, three issued a hold rating and nine gave the company’s stock a buy rating. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $24.18.

(A d)

Investors looking for companies focused on long-term growth should pay attention to these top 3 growth stocks.

One of these stocks is in the ever-popular financial space and could be one of the most talked about stocks in 2022.

Click here to download the Top 3 Growth Stocks.

Shares of FRAME opened at $19.11 on Wednesday. The company has a market capitalization of $4.33 billion, a price/earnings ratio of 39.81, a P/E/G ratio of 0.44 and a beta of 1.48. Petco Health and Wellness has a fifty-two week minimum of $16.22 and a fifty-two week maximum of $28.73. The company has a debt ratio of 0.74, a current ratio of 0.96 and a quick ratio of 0.33. The company’s 50-day moving average is $18.51 and its 200-day moving average is $20.68.

Institutional investors and hedge funds have recently been buying and selling shares of the company. Credit Suisse AG bought a new stake in shares of Petco Health and Wellness in the second quarter worth about $1,160,000. Millennium Management LLC increased its position in Petco Health and Wellness by 273.0% in the third quarter. Millennium Management LLC now owns 723,032 shares of the company worth $15,256,000 after purchasing an additional 529,187 shares during the period. Captrust Financial Advisors raised its position in Petco Health and Wellness by 2,567.1% in the third quarter. Captrust Financial Advisors now owns 15,869 shares of the company worth $335,000 after purchasing an additional 15,274 shares during the period. King Luther Capital Management Corp raised its position in Petco Health and Wellness by 62.9% in the third quarter. King Luther Capital Management Corp now owns 648,550 shares of the company worth $13,684,000 after purchasing an additional 250,450 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new position in Petco Health and Wellness in the second quarter worth $637,000. 65.22% of the shares are held by institutional investors.

Company Profile Petco Health and Wellness (Get a rating)

Petco Health and Wellness Company, Inc operates as a retailer of premium pet consumables, supplies, pets and services. The company also offers grooming services, in-store and online training, tele-vet and pet health insurance, as well as veterinary services through Vetco Clinics.

Featured Articles

Should you invest $1,000 in Petco Health and Wellness right now?

Before you consider Petco Health and Wellness, you’ll want to hear this.

While Petco Health and Wellness currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Holly Energy Partners, LP (NYSE:HEP) Receives Consensus “Hold” Recommendation from Analysts

Roland Moore — Sat, 05 Mar 2022 07:40:21 +0000

Holly Energy Partners, LP (NYSE: HEP – Get a rating) received a consensus rating of “Hold” by the eight analysts who cover the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among brokerages that have hedged the stock over the past year is $19.40.

Several research companies have recently published reports on HEP. StockNews.com downgraded shares of Holly Energy Partners from a “buy” rating to a “hold” rating in a research note on Tuesday. Barclays lowered its price target on shares of Holly Energy Partners from $17.00 to $15.00 in a Thursday, February 24 report. Zacks Investment Research downgraded the shares of Holly Energy Partners from a “hold” rating to a “sell” rating in a report on Wednesday, January 5. Raymond James lowered his price target on Holly Energy Partners shares from $21.00 to $20.00 and set an “outperform” rating on the stock in a Wednesday, February 23 report. Finally, Wells Fargo & Company downgraded Holly Energy Partners shares from a “weighted” rating to an “overweight” rating and set a target price of $22.00 on the stock in a Thursday research note. December 16.

(A d)

“There are not enough semiconductor chips in the world to meet the growing demand. But due to the global chip shortage…

These four companies are well positioned to take advantage of this rapidly growing demand over the next 12 months and beyond. ”

NYSE HEP shares opened at $16.93 on Friday. The company has a market capitalization of $1.79 billion, a P/E ratio of 8.34 and a beta of 0.92. Holly Energy Partners has a 52-week low of $15.61 and a 52-week high of $23.69. The company has a debt ratio of 2.37, a quick ratio of 1.23 and a current ratio of 1.23. The company’s 50-day moving average price is $17.87 and its 200-day moving average price is $17.97.

Holly Energy Partners (NYSE:HEP- Get a rating) last released its results on Monday, February 21. The pipeline company reported earnings per share (EPS) of $0.43 for the quarter, missing the Zacks consensus estimate of $0.48 per ($0.05). Holly Energy Partners achieved a net margin of 43.47% and a return on equity of 34.42%. The company posted revenue of $118.50 million for the quarter, versus analyst estimates of $119.37 million. In the same quarter of the previous year, the company achieved EPS of $0.49. The company’s revenue was down 7.1% year over year. Analysts expect Holly Energy Partners to post earnings per share of 2.01 for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, February 11. Shareholders of record on Tuesday, February 1 received a dividend of $0.35. This represents an annualized dividend of $1.40 and a dividend yield of 8.27%. The ex-dividend date was Monday, January 31. Holly Energy Partners’ dividend payout ratio is 68.97%.

In other news, Director James H. Lee sold 8,809 shares of the company in a trade that took place on Wednesday, December 15. The shares were sold at an average price of $16.25, for a total value of $143,146.25. The sale was disclosed in a legal filing with the SEC, accessible via this link. 0.80% of the shares are currently held by insiders of the company.

A number of institutional investors have recently changed their positions in the company. Blackstone Inc increased its position in shares of Holly Energy Partners by 211.0% in the second quarter. Blackstone Inc now owns 4,494,785 shares of the pipeline company worth $101,717,000 after purchasing an additional 3,049,403 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in the shares of Holly Energy Partners by 14.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,962,334 shares of the pipeline company valued at $65,339,000 after purchasing an additional 504,763 shares during the period. Morgan Stanley increased its stake in the shares of Holly Energy Partners by 177.3% during the 2nd quarter. Morgan Stanley now owns 514,559 shares of the pipeline company valued at $11,644,000 after purchasing an additional 329,008 shares during the period. Brookfield Asset Management Inc. increased its stake in the shares of Holly Energy Partners by 58.2% during the second quarter. Brookfield Asset Management Inc. now owns 551,340 shares of the pipeline company valued at $12,477,000 after purchasing an additional 202,936 shares during the period. Finally, Alps Advisors Inc. increased its stake in the shares of Holly Energy Partners by 3.5% during the 4th quarter. Alps Advisors Inc. now owns 5,947,463 shares of the pipeline company valued at $98,074,000 after purchasing an additional 202,307 shares during the period.

About Holly Energy Partners (Get a rating)

Holly Energy Partners LP operates a system of petroleum products and crude oil pipelines, storage tanks, distribution terminals, loading facilities and refinery processing units. It operates through Pipelines & Terminals and Refinery Process Unit segments. The company was founded in 2004 and is based in Dallas, Texas.

Further reading

Should you invest $1,000 in Holly Energy Partners right now?

Before you consider Holly Energy Partners, you’ll want to hear this.

Although Holly Energy Partners currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Research Analysts Set Fiscal 2026 Earnings Expectations for Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)

Roland Moore — Mon, 28 Feb 2022 09:02:54 +0000

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS – Get a rating) – Equity research analysts at Jefferies Financial Group released their fiscal 2026 earnings per share estimates for Ionis Pharmaceuticals in a report released Thursday, February 24. Jefferies Financial Group analyst E. Yang expects the company to post earnings per share of ($2.60) for the year.

Several other research companies have also published reports on IONS. SVB Leerink cut its target price on Ionis Pharmaceuticals from $34.00 to $29.00 and set a “market performance” rating on the stock in a research note on Friday. William Blair upgraded Ionis Pharmaceuticals from a “market performer” rating to an “outperformer” rating in a Tuesday, Dec. 14 research note. BMO Capital Markets took over coverage from Ionis Pharmaceuticals in a Friday, Dec. 10 research note. They issued a “buy” rating and a target price of $65.00 on the stock. Bank of America downgraded Ionis Pharmaceuticals from a “buy” rating to an “underperform” rating and reduced its target price for the company from $40.00 to $30.00 in a Tuesday, Feb. 1 research note . Finally, Needham & Company LLC lowered its price target on Ionis Pharmaceuticals from $84.00 to $60.00 and set a “buy” rating on the stock in a Thursday, November 4 research note. Two equity research analysts gave the stock a sell rating, five issued a hold rating and four gave the company a buy rating. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $45.05.

(A d)

URGENT: Stocks plummet after Russian invasion of Ukraine. The closure of a major pipeline to Russia could create a historic shock to oil prices and send oil inventories skyrocketing. But do NOT buy Chevron or ExxonMobil. Instead, that little Texas oil stock could get you 100+% if you get in right away, before the oil crisis gets worse.

IONS stock opened at $31.78 on Monday. The company has a debt ratio of 2.34, a current ratio of 7.71 and a quick ratio of 7.62. The company has a 50-day moving average price of $31.72 and a 200-day moving average price of $33.13. The company has a market capitalization of $4.49 billion, a P/E ratio of -83.63 and a beta of 0.88. Ionis Pharmaceuticals has a 1-year low of $25.04 and a 1-year high of $56.01. Ionis Pharmaceuticals (NASDAQ: IONS – Get a rating) last released its quarterly earnings data on Thursday, February 24. The company reported earnings per share of $1.41 for the quarter, beating the consensus estimate of $0.80 by $0.61. The company posted revenue of $440.00 million in the quarter, versus a consensus estimate of $284.08 million. Ionis Pharmaceuticals posted a negative return on equity of 4.68% and a negative net margin of 3.45%. The company’s quarterly revenue increased 51.7% year over year. In the same period a year earlier, the company posted ($2.44) earnings per share.

Major investors have recently changed their positions in the company. Amalgamated Bank increased its stake in Ionis Pharmaceuticals by 37.0% in the second quarter. Amalgamated Bank now owns 26,933 shares of the company valued at $1,074,000 after acquiring an additional 7,267 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Ionis Pharmaceuticals by 2.5% in the second quarter. Charles Schwab Investment Management Inc. now owns 713,960 shares of the company valued at $28,480,000 after acquiring an additional 17,464 shares during the period. Marshall Wace LLP acquired a new position in Ionis Pharmaceuticals in the second quarter valued at approximately $7,054,000. Kennedy Capital Management Inc. increased its stake in the shares of Ionis Pharmaceuticals by 4.0% during the 2nd quarter. Kennedy Capital Management Inc. now owns 8,329 shares of the company worth $332,000 after purchasing 321 additional shares during the period. Finally, Candriam Luxembourg SCA increased its stake in Ionis Pharmaceuticals shares by 31.5% during the 3rd quarter. Candriam Luxembourg SCA now owns 726,359 shares of the company worth $24,361,000 after purchasing an additional 173,793 shares during the period. 83.97% of the shares are held by institutional investors.

About Ionis Pharmaceuticals (Get a rating)

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through Ionis Core and Akcea Therapeutics segments. The Ionis Core segment leverages a novel drug discovery platform to generate a drug pipeline. The Akcea Therapeutics segment develops and markets drugs for cardiometabolic diseases.

See also

Should you invest $1,000 in Ionis Pharmaceuticals right now?

Before you consider Ionis Pharmaceuticals, you’ll want to hear this.

While Ionis Pharmaceuticals currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Expected to Report Earnings of $0.32 Per Share

Roland Moore — Sat, 26 Feb 2022 17:26:08 +0000

Stock analysts expect LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get a rating) will report earnings per share of $0.32 for the current fiscal quarter, Zacks reports. Three analysts provided earnings estimates for LeMaitre Vascular. The highest EPS estimate is $0.35 and the lowest is $0.30. LeMaitre Vascular posted earnings of $0.28 per share in the same quarter last year, which would indicate a positive growth rate of 14.3% year over year. The company is expected to announce its next quarterly earnings report on Thursday, May 5.

On average, analysts expect LeMaitre Vascular to report annual earnings of $1.44 per share for the current fiscal year, with EPS estimates ranging from $1.39 to $1.50. For the next fiscal year, analysts expect the company to post earnings of $1.55 per share, with EPS estimates ranging from $1.48 to $1.63. Zacks Investment Research EPS averages are an average average based on a survey of sell-side research firms that provide coverage for LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT – Get a rating) last released its results on Thursday, February 24. The medical device supplier reported earnings per share (EPS) of $0.28 for the quarter, missing Zacks’ consensus estimate of $0.31 per ($0.03). LeMaitre Vascular had a return on equity of 14.15% and a net margin of 18.21%. The company posted revenue of $39.50 million in the quarter, compared to $39.70 million expected by analysts. In the same quarter last year, the company achieved EPS of $0.34. The company’s revenue increased 5.2% year-over-year.

(A d)

It’s scientific breakthroughs like this that give investors like you the chance to get in early on the companies that will revolutionize the world…

And you might only get once in a lifetime opportunity to invest in something that big…

Several analysts have recently commented on LMAT shares. Zacks Investment Research downgraded shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Wednesday, January 26. Barrington Research lowered its price target on LeMaitre Vascular shares from $62.00 to $54.00 in a report on Friday. One research analyst rated the stock with a sell rating, one gave the stock a hold rating, and three gave the stock a buy rating. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $61.80.

NASDAQ: LMAT traded down $0.10 in Friday’s midday session, hitting $45.77. The company’s stock had a trading volume of 1,854 shares, compared to an average volume of 83,845. LeMaitre Vascular has a fifty-two week low of $39.48 and a fifty-two week high of $64.50. $. The company has a market capitalization of $999.53 million, a P/E ratio of 34.57, a P/E/G ratio of 3.06 and a beta of 1.36. The company’s 50-day moving average is $45.60 and its 200-day moving average is $50.86.

In other LeMaitre Vascular, CFO news Joseph P. Pellegrino, Jr. sold 807 shares of the company in a transaction dated Monday, December 27. The shares were sold at an average price of $52.00, for a total value of $41,964.00. The sale was disclosed in a filing with the Securities & Exchange Commission, available at the SEC website. 16.50% of the shares are currently held by insiders.

A number of hedge funds and other institutional investors have recently changed their LMAT holdings. Point72 Hong Kong Ltd purchased a new equity stake in LeMaitre Vascular during the third quarter worth approximately $54,000. Harbor Investment Advisory LLC acquired a new stock position in LeMaitre Vascular during the third quarter worth approximately $56,000. O Shaughnessy Asset Management LLC raised its position in shares of LeMaitre Vascular by 827.8% in the third quarter. O Shaughnessy Asset Management LLC now owns 1,336 shares of the medical device supplier valued at $71,000 after acquiring 1,192 additional shares last quarter. Man Group plc acquired a new equity stake in LeMaitre Vascular in the second quarter worth approximately $204,000. Finally, Quantinno Capital Management LP acquired a new equity stake in LeMaitre Vascular during the third quarter at a value of approximately $209,000. 85.82% of the shares are held by institutional investors.

LeMaitre Vascular Company Profile (Get a rating)

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sale, service and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biopatches, radiopaque marker tapes, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts and powered phlebectomies.

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Should you invest $1,000 in LeMaitre Vascular right now?

Before you consider LeMaitre Vascular, you’ll want to hear this.

While LeMaitre Vascular currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Zacks: Brokerages expect Global Medical REIT Inc. (NYSE:GMRE) to post quarterly sales of $30.06 million

Roland Moore — Sat, 19 Feb 2022 08:15:18 +0000

Wall Street brokers expect Global Medical REIT Inc. (NYSE:GMRE) to report sales of $30.06 million for the current quarter, according to Zacks. Three analysts have released earnings estimates for Global Medical REIT, with the highest sales estimate at $30.50 million and the lowest estimate at $29.78 million. Global Medical REIT reported sales of $24.93 million in the same quarter last year, suggesting a positive year-over-year growth rate of 20.6%. The company is expected to release its next quarterly results after the market closes on Monday, February 28.

On average, analysts expect Global Medical REIT to report annual revenue of $115.62 million for the current fiscal year, with estimates ranging from $115.28 million to $116.10 millions of dollars. For the next fiscal year, analysts expect the company to post sales of $128.03 million, with estimates ranging from $119.76 million to $139.24 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts who cover Global Medical REIT.

Separately, Zacks Investment Research moved shares of Global Medical REIT from a “strong sell” rating to a “hold” rating in a Tuesday, Feb. 8 research report. One investment analyst has assigned the stock a hold rating and four have assigned the stock a buy rating. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $17.20.

Hedge funds have recently changed their positions in the business. Brown Advisory Inc. purchased a new stock position in Global Medical REIT during Q4 for a value of approximately $19,389,000. Adelante Capital Management LLC purchased a new position in Global Medical REIT during Q2 at a value of $10,849,000. State Street Corp increased its position in shares of Global Medical REIT by 64.3% in the second quarter. State Street Corp now owns 1,581,093 shares of the company worth $23,649,000 after purchasing an additional 619,012 shares during the period. Allspring Global Investments Holdings LLC purchased a new stock position in Global Medical REIT in the fourth quarter at a value of $10,448,000. Finally, GEM Realty Capital increased its position in Global Medical REIT by 110.4% in the third quarter. GEM Realty Capital now owns 694,669 shares of the company valued at $10,212,000 after acquiring an additional 364,466 shares in the last quarter. 70.85% of the shares are held by institutional investors.

(A d)

These are the Penny Stock patterns that every trader should be able to spot. Two of them were responsible for my biggest winners.

Click here to get your free copy now.

GMRE opened at $16.21 on Friday. The company has a fifty-day simple moving average of $16.92 and a 200-day simple moving average of $16.16. The company has a market capitalization of $1.04 billion, a price-earnings ratio of 108.07 and a beta of 0.83. Global Medical REIT has a 12-month low of $12.82 and a 12-month high of $18.51. The company has a current ratio of 0.17, a quick ratio of 0.17 and a debt ratio of 0.90.

The company also recently declared a quarterly dividend, which was paid on Monday, January 10. Investors of record on Monday, December 27 received a dividend of $0.205 per share. The ex-dividend date was Thursday, December 23. This represents an annualized dividend of $0.82 and a yield of 5.06%. The dividend payout ratio (DPR) of Global Medical REIT is 546.70%.

Global Medical REIT Company Profile

Global Medical REIT, Inc engages in the acquisition of purpose-built healthcare facilities and the leasing of these properties to strong healthcare systems and physician groups. The company was founded on March 18, 2011 and is based in Bethesda, MD.

Recommended Stories

Get a Free Copy of Zacks Research Report on Global Medical REIT (GMRE)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Should you invest $1,000 in Global Medical REIT right now?

Before you consider Global Medical REIT, you’ll want to hear this.

While Global Medical REIT currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here

Matterport (NASDAQ:MTTR) Receives New Price Target of $23.00 at Credit Suisse Group

Roland Moore — Thu, 17 Feb 2022 13:18:45 +0000

Matterport (NASDAQ:MTTR) saw its price target lowered by Credit Suisse Group from $29.00 to $23.00 in a research report released on Thursday, Fly reports. The company currently has an “outperform” rating on the stock. Credit Suisse Group’s target price would suggest a potential upside of 190.40% from the company’s current price.

MTTR has been the subject of several other reports. Zacks Investment Research downgraded Matterport shares from a “hold” rating to a “sell” rating in a Wednesday, Jan. 5 research report. Deutsche Bank Aktiengesellschaft began covering Matterport shares in a research report on Wednesday, February 2. They issued a “buy” rating and a price target of $14.00 on the stock. Wedbush raised its price target on Matterport shares from $30.00 to $38.00 and gave the stock an “outperform” rating in a Tuesday, Nov. 30, research report. Finally, Piper Sandler lowered her price target on Matterport shares from $26.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday. One research analyst rated the stock with a sell rating and six issued a buy rating for the company’s stock. According to data from MarketBeat.com, Matterport currently has a consensus rating of “Buy” and an average price target of $17.00.

NASDAQ: MTTR opened at $7.92 on Thursday. Matterport has a fifty-two week minimum of $7.50 and a fifty-two week maximum of $37.60. The company’s fifty-day simple moving average is $15.26 and its 200-day simple moving average is $18.53.

(A d)

This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.

Matterport Inc (NASDAQ:MTTR) last released its quarterly results on Wednesday, February 16. The company reported ($0.10) earnings per share for the quarter, meeting the Zacks consensus estimate of ($0.10). The company posted revenue of $27.09 million for the quarter, versus analyst estimates of $25.14 million. The company’s revenue increased 14.8% year over year. As a group, equity research analysts expect Matterport to post -1.73 earnings per share for the current fiscal year.

A number of large investors have recently increased or reduced their stakes in the company. Wolff Wiese Magana LLC bought a new position in Matterport stock during Q4 worth approximately $26,000. Captrust Financial Advisors bought a new position in Matterport stock during Q3 for a value of approximately $34,000. Vestcor Inc bought a new position in Matterport stock during Q3 worth approximately $36,000. Destiny Wealth Partners LLC purchased a new position in Matterport stock during Q3 for a value of approximately $38,000. Finally, Rockefeller Capital Management LP increased its stake in Matterport shares by 400.0% during the 4th quarter. Rockefeller Capital Management LP now owns 1,875 shares of the company worth $38,000 after acquiring an additional 1,500 shares during the period. Institutional investors hold 26.56% of the company’s shares.

About Matterport

Matterport Inc is a spatial data company driving the digital transformation of the built world. Matterport Inc, formerly known as Gores Holdings VI, is based in SUNNYVALE, California.

Further reading

Should you invest $1,000 in Matterport right now?

Before you consider Matterport, you’ll want to hear this.

Although Matterport currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here